Whole Genome and Exome Sequencing Market

Whole Genome Sequencing sequences the complete DNA of an organism. In the case of a human this corresponds to about three billion base pairs of DNA. Whole genome sequencing entails sequencing all coding (exons) and noncoding (intron) nuclear DNA as well as mitochondrial DNA. This allows researchers to generate large quantities of data, which can then be analyzed.The exome makes up only 1.5% of the whole human genome, however ALL protein coding genes are found in the exome. Since most genetic disorders are correlated with mutations in protein coding genes, most physicians and scientists who use sequencing technologies for diagnostic purposes start with an analysis of the exome.

Whole Genome and Exome Sequencing Market contains market size and forecasts of Whole Genome and Exome Sequencing in Global, including the following market information:

• Global Whole Genome and Exome Sequencing Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Whole Genome and Exome Sequencing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

By Product Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Whole Genome and Exome Sequencing include Eurofins Scientific SE, Agilent Technologies, Inc, Beijing Genomics Institute (BGI), Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, GENEWIZ, Inc, Illumina, Inc, Laboratory Corporation of America Holdings and Novogene Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Whole Genome and Exome Sequencing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Whole Genome and Exome Sequencing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Whole Genome and Exome Sequencing Market Segment Percentages, by Type, 2021 (%)

By Product

• Kits
• Instruments

By Workflow

• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)

Global Whole Genome and Exome Sequencing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Whole Genome and Exome Sequencing Market Segment Percentages, by Application, 2021 (%)

• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Diagnostic Labs
• Research Centres, Academia and Government Institutes
• Others

Global Whole Genome and Exome Sequencing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Whole Genome and Exome Sequencing Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Whole Genome and Exome Sequencing revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Whole Genome and Exome Sequencing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eurofins Scientific SE
• Agilent Technologies, Inc
• Beijing Genomics Institute (BGI)
• Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc
• GENEWIZ, Inc
• Illumina, Inc
• Laboratory Corporation of America Holdings
• Novogene Corporation
• Oxford Nanopore Technologies, Inc
• Pacific Biosciences of California, Inc
• QIAGEN N.V
• Thermo Fisher Scientific Inc
• Cytiva